NightHawk Biosciences Confirms NYSE American Listing for Stock & Rights
Ticker: SCPX · Form: 8-K · Filed: Jan 22, 2024 · CIK: 1476963
| Field | Detail |
|---|---|
| Company | Nighthawk Biosciences, Inc. (SCPX) |
| Form Type | 8-K |
| Filed Date | Jan 22, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0002 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: corporate-governance, exchange-listing, 8-K
TL;DR
**NHWK confirms its common stock and purchase rights are still listed on NYSE American.**
AI Summary
NightHawk Biosciences, Inc. filed an 8-K on January 22, 2024, to report an event that occurred on January 19, 2024. The filing primarily updates the registration of its Common Stock and Common Stock Purchase Rights on the NYSE American LLC exchange. This matters to investors because it confirms the company's continued listing and compliance with exchange requirements, providing transparency and liquidity for their shares.
Why It Matters
This filing confirms NightHawk Biosciences' compliance with exchange listing requirements, which is crucial for maintaining investor confidence and ensuring the liquidity of its shares.
Risk Assessment
Risk Level: low — This filing is a routine update confirming existing listings and does not introduce new financial risks or operational changes.
Analyst Insight
A smart investor would note this routine filing confirms continued listing, which is a positive for liquidity, but it doesn't provide new financial or operational insights to drive investment decisions.
Key Players & Entities
- NightHawk Biosciences, Inc. (company) — the registrant filing the 8-K
- NYSE American LLC (company) — the exchange where NightHawk's securities are registered
- Common Stock (other) — one of the classes of securities registered
- Common Stock Purchase Rights (other) — another class of securities registered
- January 19, 2024 (date) — date of the earliest event reported
- January 22, 2024 (date) — date the 8-K was filed
FAQ
What is the purpose of this 8-K filing by NightHawk Biosciences, Inc.?
The purpose of this 8-K filing is to report an 'Other Event' that occurred on January 19, 2024, specifically confirming the registration of its Common Stock and Common Stock Purchase Rights on the NYSE American LLC exchange.
On which stock exchange are NightHawk Biosciences, Inc.'s securities registered?
NightHawk Biosciences, Inc.'s Common Stock and Common Stock Purchase Rights are registered on the NYSE American LLC exchange, as stated in the filing under 'Name of each exchange on which registered'.
What is the trading symbol for NightHawk Biosciences, Inc.'s Common Stock?
The trading symbol for NightHawk Biosciences, Inc.'s Common Stock is NHWK, as indicated in the 'Trading Symbol(s)' column of the filing.
Does NightHawk Biosciences, Inc. have a trading symbol for its Common Stock Purchase Rights?
No, the filing explicitly states 'None' under the 'Trading Symbol(s)' column for the Common Stock Purchase Rights.
What is the par value per share for NightHawk Biosciences, Inc.'s Common Stock?
The par value per share for NightHawk Biosciences, Inc.'s Common Stock is $0.0002, as specified in the 'Title of each class' section: 'Common Stock, $0.0002 par value per share'.
Filing Stats: 425 words · 2 min read · ~1 pages · Grade level 11.8 · Accepted 2024-01-22 08:00:09
Key Financial Figures
- $0.0002 — nge on which registered Common Stock, $0.0002 par value per share NHWK NYSE America
Filing Documents
- nhwk_8k.htm (8-K) — 26KB
- 0001079973-24-000103.txt ( ) — 236KB
- nhwk-20240119.xsd (EX-101.SCH) — 3KB
- nhwk-20240119_def.xml (EX-101.DEF) — 26KB
- nhwk-20240119_lab.xml (EX-101.LAB) — 36KB
- nhwk-20240119_pre.xml (EX-101.PRE) — 25KB
- nhwk_8k_htm.xml (XML) — 5KB
01 Other Items
Item 8.01 Other Items NightHawk Biosciences, Inc. ( the "Company") is postponing to a later date its previously announced name change which was expected to be effected on January 22, 2024. The Company will file a Current Report on Form 8-K announcing the new date prior to effecting the name change.
01 Financial Statements and
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 104 Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: January 22, 2024 NightHawk Biosciences, Inc. By: /s/ Jeff Wolf Name: Jeff Wolf Title: Chief Executive Officer